Why Xadago now?

Levodopa has limitations over time

Despite its efficacy, the therapeutic window of levodopa narrows over time1,2

Inconsistent levodopa response increases the need for adjunctive treatment options3


XADAGO is a highly selective inhibitor of monoamine oxidase B (MAO-B)4,5

  • XADAGO has over 1000-fold greater selectivity for MAO-B over MAO-A4
  • The precise mechanism by which XADAGO exerts its effects in PD is unknown4

There are no dietary restrictions at recommended doses of XADAGO4

Identifying Xadago patients

These profiles represent patients who may be appropriate for treatment with XADAGO.

MICHAEL, 57 year old male, shop owner

Patient history

First noticed right-hand tremor at age 55 and was diagnosed with Parkinson's disease (PD) a year later. He was initially started on a dopamine agonist but did not tolerate due to side effects—sometimes he would feel dizzy or more tired. He tolerated the change to carbidopa/levodopa 25/100 mg three times a day with good response.

Current status

About 1 year after starting carbidopa/levodopa, patient notes increased slowness, rigidity, and tremor with the current dose of carbidopa/levodopa. The symptoms are interfering with his work around the shop.

See how XADAGO can help patients experiencing motor fluctuations

CELIA, 62 year old female, part-time accountant

Patient history

Diagnosed with PD 4 years ago, 62-year-old female had improved motor function with carbidopa/levodopa (25 mg/100 mg) three times a day and pramipexole ER 2.25 mg.

Current status

Now she is experiencing her carbidopa/levodopa dose wearing off sooner than previously. About 30-45 minutes before each dose, she notes increased tremor and balance difficulty. She is unable to increase her pramipexole due to lower-extremity edema at higher doses. The off time impairs her work as a part-time accountant.

Learn about improving on time—without troublesome dyskinesia

XADAGO prescription savings program

Learn More
  1. Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. Drug Des Devel Ther. 2011(5):241-254.
  2. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):S11-S16.
  3. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343-348.
  4. XADAGO. Package Insert. US WorldMeds, LLC.
  5. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008;17(7):1115-1125.